Gilead Sciences (NQ:GILD)

Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares...

Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday

February 14, 2023

Via Benzinga

Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers

February 13, 2023

Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.

Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors.

ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood

February 13, 2023

Via InvestorPlace

Gilead Issues Unexpectedly Bullish Outlook After Cancer Drug Sales Rocket

February 02, 2023

The company posted another massive quarter for cancer treatment sales.

Via Investor's Business Daily

Mount Gilead, OH Author Publishes Children's Book

February 02, 2023

This Kids Book Features the Cutest Baby Elephant You Will Ever See!

Via PR Leap

Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030

February 09, 2023

The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)

Via SBWire

Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings

February 09, 2023

Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

Via Benzinga

2 Biotech Stocks That Could Make You Richer

February 09, 2023

Patience will pay off with these two stocks.

Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

February 09, 2023

The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible.

Earnings Outlook For Gilead Sciences

February 01, 2023

Via Benzinga

Thoughts For Thursday: Risk-off, Risk-on

February 09, 2023

As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.

NeurAxis: Should You Buy This IPO?

February 08, 2023

Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030

February 08, 2023

Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead...

Via SBWire

Topics Death

Is Biotech Immunocore About To Make A 25% Price Move?

February 07, 2023

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

Via MarketBeat

Topics ETFs

NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution

February 06, 2023

As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

Is Gilead Sciences a Good Stock to Buy Now?

February 06, 2023

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting

February 03, 2023

Via Benzinga

'Risk Of Overheating': 4 Experts On Hot January Jobs Report, How The Fed Will React

February 03, 2023

The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January.

Via Benzinga

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

February 03, 2023

Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact

February 03, 2023

Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...

Via Benzinga

Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?

February 03, 2023

Gilead's strongest growth since 2015 comes with an asterisk.

GILD earnings call for the period ending December 31, 2022.

Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript

February 02, 2023

Gilead Sciences Inc (NASDAQ: GILD) shares are trading higher in Thursday's after-hours session after the company reported

Why Gilead Sciences Stock Is Trading Higher After Hours

February 02, 2023

Via Benzinga

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

February 02, 2023

Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

February 02, 2023

Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029

February 02, 2023

Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG

Via SBWire

Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?

February 02, 2023

The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging.

Via Benzinga

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

February 01, 2023